Literature DB >> 3489037

Molecular analysis of an HLA-A2 functional variant CLA defined by cytolytic T lymphocytes.

A Ezquerra, N Doménech, J van der Poel, J L Strominger, M A Vega, J A López de Castro.   

Abstract

By using cytolytic T lymphocytes (CTL), the HLA-A2 serologic specificity may be divided into at least four subtypes designated as A2.1 to A2.4. The HLA-A2.4 antigen expressed by donor CLA is not recognized by allogeneic CTL specific for either A2.1, A2.2, or A2.3, but is indistinguishable from HLA-A2.1 by H-Y-specific, HLA-A2-restricted CTL and by isoelectric focusing. The structure of this HLA-A2.4 antigen was compared with the known structure of the main A2.1 subtype expressed on JY cells to establish the molecular basis for the immunologic differences between the two antigens. Comparative peptide mapping and radiochemical sequence analysis were used to establish that they differed by a single amino acid change: Phe at position 9 in HLA-A2.1 was replaced by Tyr in HLA-A2.4 from donor CLA. This position displays the highest variability score among all polymorphic residues of the class I HLA antigens. But its participation in the specific determinants recognized by CTL has not been previously established, because no other known HLA variant or H-2 mutant has been found to vary at this position. In addition, HLA-A2.4 from CLA is the only HLA-A2 subtype antigen that is identical to A2.1 in the segment spanning residues 147 to 157, a region in which all three A2.1, A2.2, and A2.3 antigens are different.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489037

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  DNA sequence of HLA-A11: remarkable homology with HLA-A3 allows identification of residues involved in epitopes recognized by antibodies and T cells.

Authors:  E P Cowan; M L Jelachich; W E Biddison; J E Coligan
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

2.  An Oriental HLA-A2 subtype is closely related to a subset of Caucasoid HLA-A2 alleles.

Authors:  H Epstein; L J Kennedy; N Holmes
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

3.  Nomenclature for factors of the HLA system, 1989. The WHO Nomenclature Committee.

Authors: 
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

4.  Molecular analysis of HLA-A2.4 functional variant KLO: close structural and evolutionary relatedness to the HLA-A2.2 subtype.

Authors:  N Doménech; R Castaño; E Goulmy; J A López de Castro
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

5.  A new public antigen shared by all HLA-A locus products except HLA-A23, -A24, -A32, and -A25 is probably influenced by the amino acid residue at position 79 in the alpha 1 domain.

Authors:  L P de Waal; C van der Meer; A R van der Horst; F H van der Velde
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

6.  Lymphocyte transformation induced by autologous cells. XVI: Distinctive role of discrete regions of class I MHC antigens in the autologous mixed leucocyte reaction.

Authors:  J B Innes; F C Garbrecht; M E Weksler; C Russo
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

7.  Structural analysis of HLA-A2.4 functional variant KNE. Implications for the mapping of HLA-A2-specific T-cell epitopes.

Authors:  N Doménech; A Ezquerra; R Castaño; J A López de Castro
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

Review 8.  Functional sites of human class I MHC molecules: paradigms a dozen?

Authors:  P Parham
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

9.  Nomenclature for factors of the HLA system, 1987.

Authors: 
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

10.  An HLA-A2 population variant with structural polymorphism in the alpha 3 region.

Authors:  R Castaño; A Ezquerra; N Doménech; J A López de Castro
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.